The facts on small-cell lung cancer, or SCLC, and non-small-cell lung cancer, or NSCLC, like symptoms, prognosis, treatment, and recovery.

Lung cancer is cancer that starts in the lungs. There are two main types of lung cancer: non-small cell lung cancer (NSCLC), which makes up 80 to 85 percent of lung cancers; and small cell lung ...

Below are survival statistics generated by the Lung Cancer Staging Project based on stage for 8,000 patients with small cell lung cancer. Image Credit: Kateryna Kon/Shutterstock.com Stage 1 ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC. Small Cell Lung Cancer (SCLC): Symptoms, Causes, Diagnosis ...

Non-small cell lung cancer: The overall five-year survival rate for large cell lung cancer is 22.8%; the overall five-year survival rate for squamous cell lung cancer is 25.2%.

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 ...

Small cell lung cancer (SCLC) is one of the most aggressive and lethal solid tumors, accounting for ~15% of the approximately 2.5 million patients diagnosed with lung cancer worldwide each year 1,2.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Small cell lung cancer (SCLC) is relatively rare to begin with, accounting for 10% to 15% of all lung cancers, according to the American Cancer Society. And the newly discovered subtype accounts ...

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial ...